Mirtazapine reduces methamphetamine use in Phase 3 trial
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 4-5
DOI: 10.1002/pu.31475 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.
Abstract (Originalsprache)
A 12‐week Phase 3 study has found that adults with moderate to severe methamphetamine use disorder who received the antidepressant mirtazapine reported a greater decrease in methamphetamine‐using days than those receiving placebo. Use of mirtazapine was not associated with any unexpected safety concerns.
Zitieren
APA
(2026). Mirtazapine reduces methamphetamine use in Phase 3 trial. The Brown University Psychopharmacology Update, 37(8), 4-5. https://doi.org/10.1002/pu.31475
Vancouver
Mirtazapine reduces methamphetamine use in Phase 3 trial. The Brown University Psychopharmacology Update. 2026;37(8):4-5. doi:10.1002/pu.31475
BibTeX
@article{euvimed2026,
title = {Mirtazapine reduces methamphetamine use in Phase 3 trial},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {4--5},
doi = {10.1002/pu.31475}
}
EUVIMED